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CanceRelationship of Race/Ethnicity and Survival after
Single Umbilical Cord Blood Transplantation for
Adults and Children with Leukemia and
Myelodysplastic Syndromes
Karen K. Ballen,1 John P. Klein,2 Tanya L. Pedersen,3 Deepika Bhatla,4 Reggie Duerst,5
Joanne Kurtzberg,6 Hillard M. Lazarus,7 Charles F. LeMaistre,8 Phillip McCarthy,9
Paulette Mehta,10 Jeanne Palmer,11 Michelle Setterholm,12 John R. Wingard,13
Steven Joffe,14 Susan K. Parsons,15 Galen E. Switzer,16 Stephanie J. Lee,17
J. Douglas Rizzo,2 Navneet S. Majhail3,18The relationship of race/ethnicity with outcomes of umbilical cord blood transplantation (UCBT) is not well
known.We analyzed the association between race/ethnicity and outcomes of unrelated single UCBT for leu-
kemia and myelodysplastic syndromes. Our retrospective cohort study consisted of 885 adults and children
(612 whites, 145 blacks, and 128 Hispanics) who received unrelated single UCBT for leukemia and myelodys-
plastic syndromes between 1995 and 2006 andwere reported to the Center for International Blood andMar-
row Transplant Research. A 5-6/6 HLA-matched unit with a total nucleated cell count infused of $2.5 
107/kg was given to 40% white and 42% Hispanic, but only 21% black patients. Overall survival at 2 years
was 44% for whites, 34% for blacks, and 46% for Hispanics (P 5 .008). In multivariate analysis adjusting for
patient, disease, and treatment factors (including HLA match and cell dose), blacks had inferior overall sur-
vival (relative risk of death, 1.31; P5.02), whereas overall survival of Hispanics was similar (relative risk, 1.03;
P5.81) to that of whites. For all patients, younger age, early-stage disease, use of units with higher cell dose,
and performance status $80 were independent predictors of improved survival. Black patients and white
patients infused with well-matched cords had comparable survival; similarly, black and white patients receiv-
ing units with adequate cell dose had similar survival. These results suggest that blacks have inferior survival
to whites after single UCBT, but outcomes are improved when units with a higher cell dose are used.
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Umbilical cord blood (UCB) is an alternative
stem-cell source for patients without HLA-matched
related or unrelated donors [1-3]. Recent results in
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the results seen in HLA-matched related donor trans-
plantation [4,5]. Many of the published studies have14Dana-Farber Cancer Institute, Boston, Massachusetts;
15Tufts Medical Center, Boston, Massachusetts; 16UPMC
Hillman Cancer Center, Pittsburgh, Pennsylanvia; 17Fred
Hutchinson Cancer Research Center, Seattle, Washington;
and 18University of Minnesota, Minneapolis, Minnesota.
Financial disclosure: See Acknowledgments on page 910.
Correspondence and reprint requests: Karen K. Ballen, MD,
Division of Hematology/Oncology, Massachusetts General
Hospital, Zero Emerson, Suite 118, Boston, MA 02114
(e-mail: kballen@partners.org).
Received September 15, 2011; accepted October 25, 2011
 2012 American Society for Blood and Marrow Transplantation
1083-8791/$36.00
doi:10.1016/j.bbmt.2011.10.040
903
904 Biol Blood Marrow Transplant 18:903-912, 2012K. K. Ballen et al.predominantly included white recipients, despite
increased ability to find donors for racial/ethnic
minorities being a purported advantage of UCB over
adult unrelated bone marrow or peripheral blood
stem-cell donors.
Analysis of hematopoietic cell transplantation
(HCT) is complex, as variables such as economic status,
delay in treatment, donor issues, matching criteria, and
biologic issues related to disease or treatmentmay all be
important contributing factors to outcomes. Previous
studies have addressed racial disparities after HLA-
matched related and unrelated donor HCT [6-9].
However, association between race/ethnicity and
UCBT outcomes has not been well described. Two
recent reports have suggested that the CD341 count
of the cord blood unit, an important prognostic factor
for transplantation outcome, may be lower in units
from black mothers than from white mothers [10,11].
Although limited by the small number of patients,
retrospective data from 122 patients transplanted with
cord blood units from the American Red Cross cord
blood banks showed no difference in survival between
whites and other groups [12].
In this study, we describe the outcomes of over 800
patients from different racial/ethnic backgrounds
receiving single-unit UCBT. These results may have
important implications for allocation of precious
resources toward UCB banks providing sufficient in-
ventory for patients of diverse backgrounds.MATERIALS AND METHODS
Data Source
The Center for International Blood and Marrow
Transplant Research (CIBMTR) comprises a volun-
tary working group of more than 500 transplantation
centers worldwide that contribute detailed data on
consecutive HCT to a statistical center at the Medical
College of Wisconsin in Milwaukee and the National
MarrowDonor Program (NMDP)Coordinating Cen-
ter in Minneapolis. Participating centers are required
to report all transplantations consecutively; compli-
ance is monitored by on-site audits. Patients are
followed longitudinally, with yearly follow-up. Com-
puterized checks for errors, physicians’ review of sub-
mitted data and on-site audits of participating centers
ensure data quality. The institutional review board and
the Privacy Officer of the Medical College of Wiscon-
sin approve observational studies conducted by the
CIBMTR with a waiver of informed consent and in
compliance with Health Insurance Portability and
Accountability Act regulations as determined.
Patients
The study included patients who received an unre-
lated single UCBT for acute lymphoblastic leukemia,acute myelogenous leukemia, myelodysplastic
syndromes, and chronic myeloid leukemia between
1995 and 2006, and were reported to the CIBMTR.
Only patients who underwent transplantation in the
United States were included. Pediatric and adult pa-
tients, and those treated with myeloablative, re-
duced-intensity, or nonmyeloablative regimens were
all included. Patients receiving multiple UCB units
were excluded, as there were too few recipients of
double-cord blood transplantation with diverse
racial/ethnic backgrounds and sufficient follow-up.
Patient and donor race/ethnicity were reported by
transplantation centers and cord blood banks, respec-
tively, according to the US Office of Management
and Budget Classification as white, black, or Hispanic
[13]. Because of their relatively small numbers (N 5
22), patients belonging to other (eg, Asian, Native
Hawaiian/Pacific Islander) and multiple race groups
were excluded from this analysis. All surviving recipi-
ents included in this analysis were retrospectively con-
tacted and provided informed consent for participation
in the NMDP research program. Informed consent
was waived by the NMDP institutional review board
for all deceased recipients. Approximately 10% of sur-
viving patients would not provide consent for use of re-
search data. To adjust for the potential bias introduced
by exclusion of nonconsenting, surviving patients,
a corrective action plan modeling process randomly
excluded the same percentage of deceased patients
[14]. The final study cohort consisted of 885 patients.
The follow-up completeness index from time of HCT,
which is the ratio of observed person-time and the po-
tential person-time of follow-up in a study, was 84%
for whites, 84% for blacks, and 73% for Hispanics at
3 years after transplantation [15].Outcomes and Study Definitions
Our primary objective was to evaluate the associa-
tion of race/ethnicity with 3-year overall survival
(OS), leukemia-free survival (LFS), relapse, and
treatment-related mortality (TRM). Secondary end-
points included neutrophil recovery (absolute neutro-
phil count of $0.5  109/L sustained for 3
consecutive days), platelet recovery (platelet count of
$20  109/L independent of platelet transfusions for
3 consecutive days), and acute and chronic graft-
versus-host disease (aGVHD, cGVHD) as assessed by
standard criteria [16,17]. All outcomes were assessed
from the date of HCT. Disease status was classified as
early, intermediate, or advanced [7,9,18]. Preparative
regimens were classified as myeloablative, reduced
intensity, or nonmyeloablative [19,20]. HLA matching
was performed at low resolution for class I and high
resolution for class II, consistent with prevalent typing
of UCB HCT during the time period covered by this
study.
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Patient-, disease-, and treatment-related factors
were compared using the c2 test and the Kruskal-
Wallis test, as appropriate. Univariate probabilities
of OS and LFS were calculated using the Kaplan-
Meier estimator [21]. Probabilities of neutrophil and
platelet recovery, aGVHD and cGVHD, TRM, and
relapse were generated using cumulative incidence es-
timates. Survival curves were compared using the log-
rank test.
The transplantation groups were compared using
proportional hazards regression models. All factors
were examined for proportional hazards using
a time-dependent covariate approach. The model
was stratified on any nonproportional hazards factor.
A model was built for the factors using a stepwise re-
gression technique. Each model included a factor for
race of the patient. First-order interactions between
race and each factor were included in the model. The
probabilities of neutrophil recovery at 60 days and
platelet engraftment at 6 months were modeled using
the pseudovalue approach [22]. The interaction be-
tween time and race was also examined. Risk factors
with P\ .05 in univariate analyses were included in
the model. Patient-related variables included age, gen-
der, Karnofsky or Lansky performance score, recipient
cytomegalovirus status, and weight at HCT. Disease-
related variables included diagnosis, disease stage at
HCT, and time from diagnosis to transplantation.
Treatment-related variables included cell dose in-
fused, HLA match, conditioning regimen intensity,
year of HCT, and donor race. For OS, LFS, TRM,
and relapse, we performed pairwise comparisons of
race and cell dose and race and HLA match; pairwise
comparisons were done adjusting for other patient-,
disease-, and treatment-related variables. We tested
for center effects using a random effects scores test in
the final regression model for each outcome [23].
All computations were performed using the statis-
tical package SAS Version 9.1 (SAS Institute, Cary,
NC).RESULTS
Patient Characteristics
Patient characteristics are outlined in Table 1. Our
cohort included 612 white patients, 145 black patients,
and 128 Hispanic patients. The median age at trans-
plantation was 8 (range: \1-78), 8 (\1-57), and 6
(\1-56) years, respectively, for the three racial/ethnic
groups, as the majority of patients receiving UCBT
in this time period were children.
Cord Blood Characteristics
Fewer blacks received well-matched UCB units
with a good cell dose compared with whites andHispanics (Table 1). Sixty-nine percent of whites,
62% of blacks, and 73% of Hispanics received a cell
dose $2.5  107 NC/kg (P 5 .08). HLA match dif-
fered among the racial/ethnic groups; a higher propor-
tion of whites (54%) received 5 of 6 or 6 of 6 HLA-A,
-B, and -DR matched UCB units compared with 30%
for blacks and 48% for Hispanics (P\ .0001). More
whites (40%) and Hispanics (42%) than blacks (21%)
received UCB units that were well matched (5 of 6
or 6 of 6 HLA matched) and had a cell dose $2.5 
107 NC/kg (P 5 .0002; Figure 1). The racial distribu-
tion of the UCB units indicates that 63% white, 30%
black, and 33% of Hispanic patients received UCB
units from donors of the same race, although race/eth-
nicity information was missing for a large proportion
of donors.
Association of Race/Ethnicity with Overall
Survival
Three-year OS rates for whites, blacks, and His-
panics were 41%, 29%, and 45%, respectively (P 5
.008) (Table 2, Figure 2). In multivariate analyses
that considered patient-, disease-, and transplant-
related variables (see Methods), blacks had worse OS,
whereas Hispanic patients had similar OS compared
with whites (Table 3).
In multivariate analysis, we also examined factors
other than race for their association with OS. Cell
dose was significantly associated with OS, whereas
HLA match did not affect OS (Table 3). We tested
for and found no significant interaction between race
and cell dose and race and HLA match. In addition
to cell dose, as expected, younger age, less advanced
disease, and performance status$80were independent
predictors of improved OS for all patients (Appendix
Table 1). Donor race did not affect OS; however, in-
formation regarding race of the cord blood donor
was missing in a substantial proportion of patients in
all three race groups. Data from 90 centers were in-
cluded in our study. However, four centers contrib-
uted .40 transplantations each and collectively
contributed to 45% of patients included in our analy-
sis. Hence, we tested for center effect and did not find
a significant center effect in our analyses.
We were also interested in evaluating whether
patients from the three race groups who received
UCB units with good cell dose and well-matched units
had comparable OS. In pairwise comparisons that ad-
justed for other patient, disease, and transplant factors
(including HLAmatch status), we found no significant
differences in OS by race among patients receiving the
same cell dose.White, Black, andHispanic patients re-
ceiving units with cell dose $2.5  107 NC/kg had
comparable OS (Table 4). Similarly, in pairwise com-
parisons (that also adjusted for cell dose), we found no
significant differences in OS by race among patients
receiving well-matched (5 of 6 or 6 of 6 HLA-A, -B,
Table 1. Characteristics of Patients with AML, ALL, CML, or MDS Receiving a Single Unrelated Umbilical Cord Blood Trans-
plantation in the United States between 1995 and 2006 and Reported to the CIBMTR
Variables
White Black/African American Hispanic/Latino
P ValueN (%) N (%) N (%)
Number of patients 612 145 128
Number of centersa 77 45 48
Patient related
Age at HCT, years, median (range) 8 (<1-78) 8 (<1-57) 6 (<1-56) .02
Age .02
0-9 334 (55) 81 (56) 88 (69)
10-17 141 (23) 34 (23) 24 (19)
18-54 113 (18) 29 (20) 15 (12)
$55 24 (4) 1 (1) 1 (1)
Male gender 336 (55) 90 (62) 80 (63) .12
Karnofsky/Lansky performance score .07
$80 553 (90) 129 (89) 115 (90)
<80 43 (7) 14 (10) 3 (2)
Missing 16 (3) 2 (1) 10 (8)
Weight at transplantation, kg, median (range) 29 (5-133) 29 (7-118) 22 (5-114) .12
Missing 1 0 3
Recipient CMV status .01
Negative 328 (54) 64 (44) 54 (42)
Positive 273 (45) 79 (54) 74 (58)
Missing 11 (2) 2 (1) 0 (.)
Disease related
Disease .15
AML 255 (42) 55 (38) 46 (36)
ALL 253 (41) 56 (39) 60 (47)
CML 30 (5) 14 (10) 11 (9)
MDS 74 (12) 20 (14) 11 (9)
Disease stage at HCTb .47
Early 184 (30) 38 (26) 38 (30)
Intermediate 262 (43) 70 (48) 63 (49)
Advanced 166 (27) 37 (26) 27 (21)
Transplantation related
Time from diagnosis to transplantation .07
#12 months 346 (57) 67 (46) 67 (52)
>12 months 266 (43) 78 (54) 61 (48)
Cell dose infused .08
<2.5  107 NC/kg 157 (26) 50 (34) 26 (20)
$2.5  107 NC/kg 420 (69) 90 (62) 93 (73)
Missing 35 (6) 5 (3) 9 (7)
CD34+ dose infused <.0001
#3.0  105/kg 171 (28) 57 (39) 17 (13)
> 3.0 x 105/kg 87 (14) 17 (12) 12 (9)
Missing 354 (58) 71 (49) 99 (77)
HLA matchc <.0001
6 of 6 match 96 (16) 6 (4) 12 (9)
5 of 6 match 230 (38) 37 (26) 50 (39)
#4 of 6 match 281 (46) 98 (68) 60 (47)
Missing 5 (1) 4 (3) 6 (5)
Gender match (donor/recipient) .43
Male/male 171 (28) 39 (27) 39 (30)
Male/female 148 (24) 25 (17) 24 (19)
Female/male 153 (25) 45 (31) 36 (28)
Female/female 112 (18) 25 (17) 24 (19)
Missing 28 (5) 11 (8) 5 (4)
Year of transplantation .20
1995-2000 207 (34) 49 (34) 33 (26)
2001-2006 405 (66) 96 (66) 95 (74)
Race of cord blood donor <.0001
White 384 (63) 34 (23) 34 (27)
African American 15 (2) 43 (30) 2 (2)
Asian/Pacific Islander 10 (2) 2 (1) 3 (2)
Hispanic 36 (6) 13 (9) 42 (33)
Otherd/unknown/missing 167 (28) 53 (37) 47 (37)
Conditioning regimen intensity .04
Myeloablative 431 (70) 98 (68) 103 (80)
Nonmyeloablative/reduced intensity 181 (30) 47 (32) 25 (20)
GVHD prophylaxis .43
Cyclosporine ± other 411 (67) 96 (66) 77 (60)
Methotrexate + cyclosporine ± other 72 (12) 18 (12) 15 (12)
FK506 ± other 125 (20) 30 (21) 33 (26)
(Continued )
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Table 1. (Continued )
Variables
White Black/African American Hispanic/Latino
P ValueN (%) N (%) N (%)
Other 4 (0) 1 (1) 3 (3)
Median follow-up, months, median (range) 52 (3-149) 37 (4-87) 36 (3-102)
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CML, chronic myeloid leukemia; CMV, cytomegalovirus; MDS, myelo-
dysplastic syndromes; NC, nucleated cell.
aTotal numbers of centers: 90.
bEarly disease included AML and ALL in first complete remission, CML in first chronic phase, and MDS with refractory anemia or refractory anemiawith
ringed sideroblasts, or bone marrow blasts <5% at HCT; intermediate disease included AML and ALL in second or greater remission or CML in accel-
erated phase or second or greater chronic phase; advanced disease included AML and ALL in relapse or primary induction failure, CML in blast phase, or
MDS with refractory anemia with excess blasts or bone marrow blasts $5% at HCT.
cHLA match is defined by low-resolution typing at HLA-A and -B, and high-resolution typing at -DRB1.
dIncludes multiple race and Native American.
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relatively small number of black and Hispanic patients
in our cohort, we could not perform multivariate anal-
yses in the subgroup of patients who received well-
matched units with adequate cell dose. However, in
unadjusted analyses, black patients receiving HLA 5
of 6 or 6 of 6 matched UCB unit with a cell dose
$2.5 107 NC/kg (N5 26) had similar OS compared
with white patients receiving units of similar cell dose
and HLA match (Figure 3).
LFS
Three-year LFS for whites, blacks, and Hispanics
was 38%, 29%, and 39%, respectively (P 5 .04)
(Table 2). In multivariate analyses, there was no signif-
icant difference in LFS among racial groups (Table 3).
As with OS, cell dose influenced LFS while HLA
match status did not (Table 3). As with OS, in pairwise
comparisons, there was no difference in LFS among
white, Hispanic, and black patients receiving UCB
units with similar cell dose and among patients receiv-
ing well-matched units (Table 4). For all patients,
transplantation for advanced disease, older age at
transplantation, and performance status of \80 ad-
versely affected LFS, whereas HCT for myelodysplas-
tic syndromes was associated with better LFS
(Appendix Table 1).Figure 1. Distribution of UCB units based on race, cell dose, and HLA
match.TRM and Relapse
Table 2 highlights cumulative incidences of TRM
and relapse. In multivariate analysis adjusting for other
important variables including cell dose and HLA
match, race had no influence on risk of relapse or
TRM (Table 3).
Cell dose and HLA match status did not signifi-
cantly affect the risks of relapse (Table 3). There was
no difference in relapse risks when we compared white,
Hispanic, and black patients who had received units
with good cell dose and units with good HLA match
(Table 4).
In multivariate analyses, there was no difference in
the relative risks of TRM by race (Table 3). Both cell
dose and HLA match were significant predictors of
TRM. On pairwise comparisons, white, Hispanic,
and black patients receiving units with cell dose
$2.5  107 NC/kg had comparable TRM (Table 4).
Similarly, white, Hispanic, and black patients who
received 5 of 6 HLA-matched units also had similar
risks of TRM (Table 4).
Engraftment and GVHD
The median time to neutrophil recovery was 23
(range, 1-104) days, and there was no difference among
racial/ethnic groups (Table 2). The median time to
platelet recovery was 59 (range, 1-241) days, again
with no difference among racial/ethnic groups. In
multivariate analysis, race had no independent associ-
ation with the likelihood of neutrophil engraftment or
platelet engraftment. As expected, cell dose was an
independent predictor of neutrophil and platelet en-
graftment. In multivariate analysis, race was not asso-
ciated with risks of aGVHD or cGVHD.
Causes of Death
Causes of death differed slightly among the differ-
ent groups. For all patients, relapse was a major cause
of death; 37% of white patients (N 5 129), 46% of
Hispanics (N 5 31), and 38% of black patients (N 5
38) who died succumbed to relapsed disease. For white
(N 5 86, 25%) and Hispanic (N 5 17, 25%) patients,
Table 2. UnivariateOutcomes of Patients with AML, ALL, CML, orMDSReceiving a Single Unrelated Cord Blood Transplantation
between 1995 and 2006 and Reported to the CIBMTR
Outcome Event
White Black Hispanic
P ValueN Probability (95% CI) N Probability (95% CI) N Probability (95% CI)
Overall survival, 3 years 612 41 (37-45)% 145 29 (22-38)% 128 45 (35-54)% .008b
Leukemia-free survival, 3 years 607 38 (34-42)% 144 29 (22-37)% 127 39 (31-49)% .04b
Relapse, 3 years 607 27 (23-30)% 144 29 (22-37)% 127 31 (23-40)% .60a
Treatment-related mortality, 3 years 607 35 (31-39)% 144 41 (33-50)% 127 30 (22-38)% .15a
Neutrophil engraftment, 60 days 605 86 (83-88)% 145 81 (74-87)% 127 86 (79-91)% .40a
Platelet engraftment, 6 months 602 62 (58-66)% 139 52 (44-61)% 126 67 (58-75)% .05a
Acute GVHD (grades 2-4), 100 days 608 50 (46-54)% 145 50 (42-59)% 127 56 (47-65)% .42a
Chronic GVHD, 2 years 598 24 (20-27)% 143 21 (14-28)% 125 30 (22-39)% .24a
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CML, chronic myeloid leukemia; CI, confidence interval; CMV, cytomeg-
alovirus; MDS, myelodysplastic syndromes.
aCumulative incidence estimate with pointwise P value.
bLog-rank P value.
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after relapse. For black patients, organ failure (N5 15,
15%) was the second most common cause of death.
Death from GVHD was rare in all groups (whites,
N 5 22 [6%], Hispanics, N 5 1 [1%], blacks, N 5 8
[8%]).DISCUSSION
This report examines the association of racial/ethnic
backgroundof the recipientwithoutcomes afterUCBT.
Results indicate that black patients have inferior OS
compared with white patients after single UCB trans-
plantation.Thisdisparity inoutcomes ispartially a result
of the inability to find a well-matched, appropriately
sized UCB unit for black patients, as fewer black than
white patients received UCB that were 5 of 6 or 6 of 6
HLA matched and had a cell dose of .2.5  107 NC/
kg. In contrast, when the analysis was restricted to pa-
tients receiving well-matched units and units with ade-
quate cell dose, there was no significant difference in
survival by race. These results suggest that the increased
difficulty in finding appropriately matched cord units of
sufficient cell dosemay be amajor obstacle to better out-
comes in black patients. Furthermore, the poorer out-
comes in black patients may be improved by infusing0
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Figure 2. Unadjusted overall survival of white, black, and Hispanic pa-
tients receiving single umbilical cord blood transplantation.UCBunitswith sufficient cell dose. As reported by other
investigators, outcomes were better among all patients
when transplanted with a higher cell dose. Death from
GVHD was low in all groups [24].
This study has some limitations. The majority of
patients included in this analysis were children. Geo-
graphic variation in distribution of racial/ethnic groups
in the United States and extensive UCB transplanta-
tion experience could lead to strong center effects.
However, transplantation center was not a significant
correlate of OS in our analysis. Although use of double
cord blood HCT has been increasingly used in adults,
too few transplantations in a racially/ethnically diverse
population with adequate follow-up were available
during the study time period. A future study of racial
disparities after double cord blood transplantation is
planned. Small patient numbers limited the ability to
understand differences in the causes of death. We
could not robustly evaluate the impact of using race-
matched versus mismatched UCB units on outcomes
because these data were missing for a large proportion
of donor units. Race/ethnicity was reported by trans-
plantation centers and cord blood banks and was not
verified. Furthermore, there may have been differences
in access to posttransplantation care or posttransplan-
tation medications among racial/ethnic groups that
could not be addressed in this study [3,25]. We could
not evaluate the effect of patient socioeconomic
status in our study, as zip code data were not
available for a large proportion of patients. In
a previous study, socioeconomic status estimated by
zip code of residence was found to be an independent
predictor of OS and TRM following unrelated donor
HCT for acute and chronic leukemia [9].
Although there was a difference in OS by race, the
risks of LFS, relapse, and TRM were not significantly
different among white and black patients. Because of
the relatively small number of black patients available
for our analysis, our study may have lacked the power
to detect any association of race with outcomes other
than OS. Studies with a larger number of minority
Table 3. Multivariate Analysis for Outcomes of Single Un-
related Umbilical Cord Blood Transplantation for AML, ALL,
CML, or MDS
Endpoint N Relative Risk 95% CI P Value
Overall survivala
Race/ethnicityb
White 612 1.00
Black 145 1.31 1.04 1.66 .02
Hispanic 128 1.03 0.79 1.35 .80
Cell dose infusedb
$2.5  107 NC/kg 603 1.00
<2.5  107 NC/kg 233 1.44 1.15 1.80 .001
Missing 49 1.22 0.83 1.80 .31
HLA matchc
6/6 114 1.00
5/6 317 1.01 0.74 1.37 .95
4/6 439 1.25 0.93 1.67 .13
Missing 15 1.77 0.88 3.49 .11
Leukemia-free survivald
Race/ethnicityb
White 607 1.00
Black 144 1.25 0.99 1.58 .06
Hispanic 127 1.01 0.78 1.31 .95
Cell dose infusedb
$2.5  107 NC/kg 600 1.00
<2.5  107 NC/kg 229 1.32 1.11 1.73 .004
Missing 56 1.08 1.09 1.59 .66
HLA matchc
6 of 6 113 1.00
5 of 6 314 1.01 0.75 1.35 .89
4 of 6 436 1.21 0.92 1.61 .18
Missing 22 1.69 0.85 3.37 .14
Relapsef
Race/ethnicityb
White 607 1.00
Black 144 1.40 0.96 2.03 .08
Hispanic 127 1.13 0.77 1.63 .53
Cell dose infusedb
$2.5  107 NC/kg 600 1.00
<2.5  107 NC/kg 229 1.18 0.67 2.08 .56
Missing 49 1.00 0.68 1.46 .99
HLA matchc
6 of 6 113 1.00
5 of 6 314 0.71 0.48 1.04 .08
4 of 6 436 0.77 0.52 1.14 .19
Missing 15 1.40 0.50 4.17 .54
Treatment-related mortalitye
Race/ethnicityb
White 607 1.00
Black 144 1.18 0.87 1.58 .29
Hispanic 127 0.92 0.64 1.31 .63
Cell dose infusedb
$2.5  107 NC/kg 600 1.00
<2.5  107 NC/kg 229 1.67 1.26 2.19 .0003
Missing 56 0.92 0.56 1.53 .75
HLA matchc
6 of 6 113 1.00
5 of 6 314 1.52 0.96 2.39 .07
4 of 6 436 2.05 1.33 3.17 .001
Missing 22 2.52 1.00 6.325 .05
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous
leukemia; CML, chronic myeloid leukemia; CI, confidence interval;
CMV, cytomegalovirus; MDS, myelodysplastic syndromes; NC, nucle-
ated cell.
aOther variables significantly associated with overall survival were diag-
nosis, disease status, age, and performance status score (see Appendix
Table 1).
bc2 test with 2 df.
cc2 test with 3 df.
dOther variables significantly associated with leukemia-free survival
were diagnosis, disease status, age, and performance status score (see
Appendix Table 1).
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nomic status) remain necessary to better understand
the reason for differences in survival between white
and black patients after UCBT. Nevertheless, an im-
portant finding from our study was that white and
black patients who received units with adequate cell
dose had similar risks of mortality. Similarly, white
and black patients who received HLA well-matched
units had comparable survival. Hence, survival dispar-
ities by race/ethnicity after UCBT could partly be
overcome by availability of UCB units with adequate
cell dose and HLA match.
Despite extensive recruiting efforts, it remains
more difficult for blacks and other racial minorities to
find matched adult unrelated donor volunteers via the
NMDP. Donor selection using antigen level typing
for class I and allele level typing for class II uncovers
at least one fully matched adult volunteer donor for
79% of white patients, 40% of black patients, and
57% of Hispanic patients [26]. With more stringent
contemporary criteria for HLA matching, the likeli-
hood of finding a well-matched donor for racial minor-
ities is likely even lower. A prospective analysis from
Memorial Sloan-Kettering Cancer Center revealed
that a 10 of 10 allele level matched adult unrelated
donorwas identified for 53%of patientswithEuropean
ancestry and 21% of patients with non-European
ancestry [27]. In contrast, 56% of patients receiving
a UCB transplantation were of non-European ances-
try.However, an early study of five different cord blood
banks found no increase in cord blood collections from
minorities when compared with bone marrow collec-
tions from minorities in the same geographic area
[28]. The American Red Cross cord blood banks at-
tempted to increase diversity by establishing banks in
different areas of the United States, which resulted in
a cord blood donor pool of 64% whites, 16% blacks,
12% Hispanics, 4% Asians, 1% Native Americans,
and 3% other [10]. Although the proportion of minor-
ity donors may match the distribution of the US popu-
lation, greater HLA diversity in the black population
and a higher proportion of UCB units of low cell
dose, may limit the number of high-quality UCB units
available to black patients [10,11]. Extensive resources
have been allocated in theUnited States andworldwide
to create a large, diverse cord blood donor pool.
Black patients have been reported to have a higher
mortality than white patients in both sibling and
unrelated donor transplantations [9,29]. However,
other studies restricted to HLA matched sibling
transplantations showed that Hispanics had a higher
risk of overall mortality after transplantation,eOther variables significantly associated with transplantation-related
mortality were disease status and age (see Appendix Table 1).
fOther variables significantly associated with relapse were diagnosis, dis-
ease status, age, performance status score, gender, and time from diag-
nosis to transplantation (see Appendix Table 1).
Table 4. Pairwise Comparisons of (1) Race and Cell Dose and (2) Race and HLA Match for White, Hispanic, and Black Patients
Receiving Single Unrelated Umbilical Cord Blood Units with Adequate Cell Dose and with Adequate HLA Match
Cell Dose HLA Matcha
Race/Cell Dose N Relative Risk 95% CI P Value Race/HLA Match N Relative Risk 95% CI P Value
Overall Survival
White, $2.5  107 NC/kg 420 1.00 White, 5/6 match 230 1.00
Hispanic, $2.5  107 NC/kg 93 0.92 0.65 1.30 .63 White, 6/6 match 96 0.84 0.59 1.35 .32
Black, $2.5  107 NC/kg 90 1.26 0.93 1.70 .13 Hispanic, 5/6 match 49 0.86 0.55 1.35 .49
Black, 5/6 match 37 1.22 0.76 1.97 .41
Leukemia-free survival
White, $2.5  107 NC/kg 417 1.00 White, 5/6 match 228 1.00
Hispanic, $2.5  107 NC/kg 93 0.93 0.68 1.29 .67 White, 6/6 match 95 0.84 0.60 1.13 .31
Black, $2.5  107 NC/kg 90 1.20 0.89 1.61 .24 Hispanic, 5/6 match 49 0.84 0.55 1.29 .43
Black, 5/6 match 37 1.10 0.68 1.76 .70
Relapse
White, $2.5  107 NC/kg 417 1.00 White, 5/6 match 228 1.00
Hispanic, $2.5  107 NC/kg 93 0.98 0.63 1.53 .94 White, 6/6 match 95 1.27 0.81 1.96 .28
Black, $2.5  107 NC/kg 90 1.30 0.85 2.00 .23 Hispanic, 5/6 match 49 1.02 0.58 1.79 .93
Black, 5/6 match 37 1.14 0.58 2.24 .71
Treatment-related mortality
White, $2.5  107 NC/kg 417 1.00 White, 5/6 match 228 1.00
Hispanic, $2.5  107 NC/kg 93 0.89 0.55 1.42 .62 White, 6/6 match 95 0.46 0.27 0.80 .005
Black, $2.5  107 NC/kg 90 1.16 0.77 1.74 .47 Hispanic, 5/6 match 49 0.65 0.33 1.25 .20
Black, 5/6 match 37 1.08 0.55 2.10 .82
CI indicates confidence interval.
Analyses were adjusted for other patient-, disease-, and transplantation-related factors (analysis by cell dose also adjusted for HLAmatch and analysis by
HLA match also adjusted for cell dose).
aBecause of a relatively small number of patients, data on black patients (N5 6) and Hispanic patients (N5 12) who received 6 of 6 HLA matched units
are not included in this table.
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outcomes [7,30]. Black patients are known to have
greater genetic diversity and HLA polymorphisms,
making matching for minor antigens less likely [31].
Increasing genetic diversity at minor transplantation
antigens may affect survival after transplantation, and
these differences may be even more important in
UCBT given the greater degree of mismatch com-
pared with unrelated donor transplantation [32]. Al-
though this cord blood study has fewer patients than
the transplantation studies using sibling or unrelated
donors cited previously, we have been able to identify
a potential solution to the discrepancy in outcomes,
with the use of larger and better matched cord blood
units. In addition, because the growth of UCB banks
and transplantation was specifically designed to aidFigure 3. Unadjusted overall survival of white and black patients re-
ceiving umbilical cord blood units with 5 of 6 or 6 of 6 HLA match
and cell dose $2.5  107 NC/kg.populations underrepresented in the traditional trans-
plantation registries, the new information presented
here on race/ethnicity and UCBT outcomes is of im-
portance to transplantation physicians, cord blood
banks, and policy makers.
This report examines for the first time the out-
comes of UCBT for the different racial/ethnic groups.
These results suggest that blacks have inferior survival
rates to whites after single UCBT. Outcomes for black
andwhite patients are improvedwhenunits with higher
cell doses are infused.The resources to collect a diverse
UCB donor pool and to ensure UCB of high cell dose
are extensive, but this report suggests the need to
redouble these efforts in order to better meet the needs
of the diverse population of transplantation patients.ACKNOWLEDGMENTS
The authors acknowledge Mary Eapen, MD, MS,
Associate Scientific Director, Center for International
Blood and Marrow Transplant Research for her help-
ful review of the manuscript.
Financial disclosure: The CIBMTR is supported by
Public Health Service Grant/Cooperative Agreement
U24-CA76518 from the National Cancer Institute
(NCI), the National Heart, Lung and Blood Institute
(NHLBI), and the National Institute of Allergy
and Infectious Diseases (NIAID); a Grant/
Cooperative Agreement 5U01HL069294 from
NHLBI and NCI; a contract HHSH234200637015C
with Health Resources and Services Administration
Biol Blood Marrow Transplant 18:903-912, 2012 911Race and Outcomes of UCBT(HRSA/DHHS); two Grants N00014-06-1-0704 and
N00014-08-1-0058 from the Office of Naval Re-
search; and grants from AABB; Allos, Inc.; Amgen,
Inc.; Anonymous donation to the Medical College of
Wisconsin; Astellas Pharma US, Inc.; Be the Match
Foundation; Biogen IDEC; BioMarin Pharmaceutical,
Inc.; Biovitrum AB; BloodCenter of Wisconsin; Blue
Cross and Blue Shield Association; Bone Marrow
Foundation; Buchanan Family Foundation; Cari-
dianBCT; Celgene Corporation; CellGenix, GmbH;
Children’s Leukemia Research Association; ClinIm-
mune Labs; CTI Clinical Trial and Consulting Ser-
vices; Eisai, Inc.; Genentech, Inc.; Genzyme
Corporation; Histogenetics, Inc.; HKSMedical Infor-
mation Systems; Hospira, Inc.; Kirin Brewery Co.,
Ltd.; The Leukemia & Lymphoma Society; Merck &
Company; The Medical College of Wisconsin; Mil-
lennium Pharmaceuticals, Inc.; Miller Pharmacal
Group;MillimanUSA, Inc.; Miltenyi Biotec, Inc.; Na-
tional Marrow Donor Program; Nature Publishing
Group; Novartis Oncology; Oncology Nursing Soci-
ety; Osiris Therapeutics, Inc.; Otsuka America Phar-
maceutical, Inc.; Pall Life Sciences; Pfizer Inc;
Schering Corporation; Sigma-Tau Pharmaceuticals;
Soligenix, Inc.; StemCyte, Inc.; StemSoft Software,
Inc.; Sysmex America, Inc.; THERAKOS, Inc.; Vida-
care Corporation; ViraCor Laboratories; Viro-
Pharma, Inc.; and Wellpoint, Inc. The views
expressed in this article do not reflect the official policy
or position of the National Institutes of Health, the
Department of the Navy, the Department of Defense,
or any other agency of the US Government.AUTHORSHIP STATEMENT
Conception and design: Karen K. Ballen, Navneet
S. Majhail, John P. Klein. Provision of study materials
or patients: Deepika Bhatla, Reggie Duerst, Joanne
Kurtzberg, Hillard Lazarus, Charles F. LeMaistre,
Phillip McCarthy, Paulette Mehta, Jeanne Palmer,
JohnR.Wingard. Collection and assembly of data: Ta-
nya L. Pedersen,Navneet S.Majhail. Data analysis and
interpretation: Karen K. Ballen, Navneet S. Majhail,
John P. Klein, Tanya L. Pedersen, Deepika Bhatla, Re-
ggie Duerst, Joanne Kurtzberg, Hillard Lazarus,
Charles F. LeMaistre, Phillip McCarthy, Paulette
Mehta, Jeanne Palmer, Michelle Setterholm, John R.
Wingard, Steven Joffe, Susan K. Parsons, Galen Swit-
zer, Stephanie J. Lee, J. Douglas Rizzo. Manuscript
writing: Karen K. Ballen, Navneet S. Majhail, John P.
Klein, Tanya L. Pedersen, Deepika Bhatla, Reggie
Duerst, Joanne Kurtzberg, Hillard Lazarus, Charles
F. LeMaistre, Phillip McCarthy, Paulette Mehta,
Jeanne Palmer, Michelle Setterholm, John R. Wing-
ard, Steven Joffe, SusanK.Parsons,Galen Switzer, Ste-
phanie J. Lee, J. Douglas Rizzo. Final approval of
manuscript: Karen K. Ballen, Navneet S. Majhail,John P. Klein, Tanya L. Pedersen, Deepika Bhatla,
Reggie Duerst, Joanne Kurtzberg, Hillard Lazarus,
Charles F. LeMaistre, Phillip McCarthy, Paulette
Mehta, Jeanne Palmer, Michelle Setterholm, John R.
Wingard, Steven Joffe, Susan K. Parsons, Galen
Switzer, Stephanie J. Lee, J. Douglas Rizzo.AUTHOR CONFLICTOF INTEREST
STATEMENT
The authors have no conflicts of interest to declare.REFERENCES
1. Ballen KK. New trends in umbilical cord blood transplantation.
Blood. 2005;105:3786-3792.
2. Wagner JE, Barker JN, DeFor TE, et al. Transplantation of un-
related donor umbilical cord blood in 102 patients with malig-
nant and nonmalignant diseases: influence of CD34 cell dose
and HLA disparity on treatment-related mortality and survival.
Blood. 2002;100:1611-1618.
3. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after
transplantationof cordbloodor bonemarrow fromunrelated do-
nors in adults with leukemia.NEngl JMed. 2004;351:2265-2275.
4. Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of trans-
plantation of unrelated donor umbilical cord blood and bone
marrow in children with acute leukaemia: a comparison study.
Lancet. 2007;369:1947-1954.
5. Eapen M, Rocha V, Sanz G, et al. Effect of graft source on un-
related donor haematopoietic stem-cell transplantation in adults
with acute leukemia: a retrospective analysis. Lancet Oncol. 2010;
11:653-660.
6. Davies SM, Kollman C, Anasetti C, et al. Engraftment and sur-
vival after unrelated-donor bone marrow transplantation: a re-
port from the National Marrow Donor Program. Blood. 2000;
96:4096-4102.
7. Serna DS, Lee SJ, Zhang MJ, et al. Trends in survival rates after
allogeneic hematopoietic stem-cell transplantation for acute and
chronic leukemia by ethnicity in theUnited States andCanada. J
Clin Oncol. 2003;21:3756-3760.
8. Oh H, Loberiza FR Jr, Zhang MJ, et al. Comparison of graft-
versus-host-disease and survival after HLA-identical sibling
bone marrow transplantation in ethnic populations. Blood.
2005;105:1408-1416.
9. Baker KS, Davies SM, Majhail NS, et al. Race and socioeco-
nomic status influence outcomes of unrelated donor hematopoi-
etic cell transplantation. Biol Blood Marrow Transplant. 2009;15:
1543-1554.
10. Ballen KK, Kurtzberg J, Lane TA, et al. Racial diversity with
high nucleated cell counts andCD34 counts achieved in national
network of cord blood banks. Biol Blood Marrow Transplant.
2004;10:269-275.
11. Cairo MS, Wagner EL, Fraser J, et al. Characterization of
banked umbilical cord blood hematopoietic progenitor cells
and lymphocyte subsets and correlation with ethnicity, birth
weight, sex, and type of delivery: a Cord Blood Transplantation
(COBLT) study report. Transfusion. 2005;45:856-866.
12. Ballen KK, Haley NR, Kurtzberg J, et al. Outcomes of 122 di-
verse adult and pediatric cord blood transplant recipients from
a large cord blood bank. Transfusion. 2006;46:2063-2070.
13. Revisions to the Standards for the Classification of Federal Data
on Race and Ethnicity. Office of Management and Budget.
Available at: http://www.whitehouse.gov/omb/fedreg_1997
standards/. Accessed February 25, 2011.
14. Farag SS, Bacigalupo A, EapenM, et al. The effect of KIR ligand
incompatibility on the outcome of unrelated donor transplanta-
tion: a report from the Center for International Blood and Mar-
row Transplant Research, the European Blood and Marrow
ppendix Table 1. (Continued )
Endpoint/Variable Relative Risk 95% CI P Value
Disease status at HCT
Early 1.00 <.01
Intermediate 1.01 0.80 1.27 .95
Late 1.80 1.43 2.26 <.01
Age
<10 years 1.00 <.01
10-17 years 1.07 0.84 1.35 .59
18-54 years 1.47 1.13 1.91 <.01
$55 years 2.00 1.24 3.22 <.01
KPS score at HCT
$80 1.00 <.01
<80 1.60 1.17 2.19 <.01
Missing 0.81 0.47 1.42 .45
Leukemia-free survival
Diagnosis
AML 1.00 <.01
ALL 0.88 0.72 1.07 .19
CML 0.76 0.53 1.10 .15
MDS 0.60 0.44 0.81 <.01
Disease status at HCT
Early 1.00 <.01
Intermediate 0.98 0.78 1.22 .83
Late 1.80 1.43 2.26 <.01
Age
<10 years 1.00 <.01
10-17 years 0.94 0.75 1.19 .62
18-54 years 1.41 1.10 1.82 <.01
$55 years 1.85 1.15 2.98 .01
KPS score at HCT
$80 1.00 <.01
<80 1.55 1.14 2.10 <.01
Missing 0.97 0.57 1.62 .88
Relapse
Diagnosis
AML 1.00 <.01
ALL 0.78 0.57 1.07 .13
CML 0.88 0.50 1.54 .64
MDS 0.34 0.21 0.56 <.01
Disease status at HCT
Early 1.00 <.01
Intermediate 1.19 0.80 1.77 .39
Late 2.87 2.02 4.09 <.01
Age
<10 years 1.00 <.01
10-17 years 0.47 0.31 0.73 .06
18-54 years 0.88 0.59 1.31 .52
$55 years 1.93 0.98 3.82 .06
KPS score at HCT
$80 1.00 <.01
<80 2.10 1.34 3.30 <.01
Missing 0.92 0.41 2.10 .84
Sex
Male 1.00 <.01
Female 1.56 1.20 2.04 <.01
Time from DX to TX
>12 months 1.00 .03
912 Biol Blood Marrow Transplant 18:903-912, 2012K. K. Ballen et al.Transplant Registry, and the Dutch Registry. Biol Blood Marrow
Transplant. 2006;12:876-884.
15. Clark TG, Altman DG, De Stavola BL. Quantification of the
completeness of follow-up. Lancet. 2002;359:1309-1310.
16. Prezpiorka D,Weisdorf D, Martin P, et al. 1994 consensus con-
ference on acuteGVHDgrading. BoneMarrow Transplant. 1995;
15:825-828.
17. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-
host disease and other late complications of bone marrow trans-
plantation. Semin Hematol. 1991;28:250-259.
18. Ringden O, Pavletic SZ, Anasetti C, et al. The graft-versus-
leukemia effect using matched unrelated donors is not superior
to HLA-identical siblings for hematopoietic stem cell transplan-
tation. Blood. 2009;113:3110-3118.
19. Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning
regimen workshop: defining the dose spectrum. Report of a work-
shopconvenedby theCenter for InternationalBoneMarrowTrans-
plant Research. Biol Blood Marrow Transplant. 2009;15:367-369.
20. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of
conditioning regimens: working definitions. Biol Blood Marrow
Transplant. 2009;15:1628-1633.
21. Cox DR. Regressionmodels and life tables (with discussion). J R
Stat Soc, Ser B (Stat Method). 1972;34:187-220.
22. Klein JP. Modelling competing risks in cancer studies. Stat Med.
2006;25:1015-1034.
23. Commenges D, Andersen PK. Score test of homogeneity for
survival data. Lifetime Data Anal. 1995;1:145-156.
24. Ballen KK, Spitzer TR, Yeap BY, et al. Double unrelated
reduced-intensity umbilical cord blood transplantation in
adults. Biol Blood Marrow Transplant. 2007;13:82-89.
25. Majhail NS, Omondi NA, Denzen E, Murphy EA, Rizzo JD.
Access to hematopoietic cell transplantation in the United
States. Biol Blood Marrow Transplant. 2010;16:1070-1075.
26. KollmanC, Abella E, Baitty RL, et al. Assessment of optimal size
and composition of the U.S. National Registry of hematopoietic
stem cell donors. Transplantation. 2004;78:89-95.
27. Barker JN, Byam CE, Kernan NA, et al. Availability of cord
blood extends allogeneic hematopoietic stem cell transplant ac-
cess to racial and ethnicminorities. Biol BloodMarrow Transplant.
2010;16:1541-1548.
28. BallenKK,Hicks J,DharanB, et al. Racial and ethnic composition
of volunteer cord blood donors: comparison with volunteer unre-
lated marrow donors. Transfusion. 2002;42:1279-1284.
29. Mielcarek M, Gooley T, Martin PJ, et al. Effects of race on sur-
vival after stem cell transplantation. Biol Blood Marrow Trans-
plant. 2005;11:231-239.
30. Baker KS, Loberiza FR Jr, Yu H, et al. Outcome of ethnic mi-
norities with acute or chronic leukemia treated with hematopoi-
etic stem-cell transplantation in the United States. J Clin Oncol.
2005;23:7032-7042.
31. Lohmueller KE, Indap AR, Schmidt S, et al. Proportionally
more deleterious genetic variation in European than in African
populations. Nature. 2008;451:994-997.
32. Dickinson AM, Harrold JL, Cullup H. Haematopoietic stem
cell transplantation: can our genes predict clinical outcome? Ex-
pert Rev Mol Med. 2007;9:1-19.Appendix Table 1. FactorsOther Than Race, Cell Dose, and
HLA Match (Shown in Table 3) That Were Significantly Asso-
ciated with Outcomes of Single Unrelated Umbilical Cord
Blood Transplantation for AML, ALL, CML, or MDS
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(Continued )A#12 months 0.68 0.48 0.96 .03
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ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous
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lodysplastic syndromes.
